Hide metadata

dc.date.accessioned2020-05-21T18:15:52Z
dc.date.available2021-03-15T23:45:42Z
dc.date.created2019-03-19T15:26:05Z
dc.date.issued2019
dc.identifier.citationWu, Iren Yeeling Nikolaisen, Trygg Einar Skalko-Basnet, Natasa Di Cagno, Massimiliano Pio . The hypotonic environmental changes affect liposomal formulations for nose-to-brain targeted drug delivery. Journal of Pharmaceutical Sciences. 2019, 108(8), 2570-2579
dc.identifier.urihttp://hdl.handle.net/10852/76064
dc.description.abstractSystemic administration of drugs is ineffective in the treatment of central nervous system disorders because of the blood-brain barrier. Nasal administration has been suggested as an alternative administration route as drugs absorbed in the olfactory epithelium bypass the blood-brain barrier and reach the brain within minutes. However, the nasal mucosa properties (e.g., tonicity, pH) are not constant because of physiological and environmental factors, and this might limit the therapeutic outcome of nanocarrier-based formulations. To shine light on the impact of environmental ionic strength on nanocarrier-based formulations, we have studied how liposomal formulations respond to the change of tonicity of the external environment. Large unilamellar vesicles loaded with 6 different drugs were exposed to different hypotonic environments, creating an osmotic gradient within the inner core and external environment of the liposomes up to 650 mOsm/kg. Both size and polydispersity of liposomes were significantly affected by tonicity changes. Moreover, the release kinetics of hydrophilic and lipophilic drugs were largely enhanced by hypotonic environments. These results clearly demonstrate that the environmental ionic strength has an impact on liposomal formulation stability and drug release kinetics and it should be considered when liposomal formulations for nose-to-brain targeted drug delivery are designed.en_US
dc.languageEN
dc.titleThe hypotonic environmental changes affect liposomal formulations for nose-to-brain targeted drug deliveryen_US
dc.typeJournal articleen_US
dc.creator.authorWu, Iren Yeeling
dc.creator.authorNikolaisen, Trygg Einar
dc.creator.authorSkalko-Basnet, Natasa
dc.creator.authorDi Cagno, Massimiliano Pio
cristin.unitcode185,15,23,10
cristin.unitnameGalenisk farmasi og samfunnsfarmasi
cristin.ispublishedtrue
cristin.fulltextpostprint
cristin.qualitycode2
dc.identifier.cristin1686015
dc.identifier.bibliographiccitationinfo:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Journal of Pharmaceutical Sciences&rft.volume=108&rft.spage=2570&rft.date=2019
dc.identifier.jtitleJournal of Pharmaceutical Sciences
dc.identifier.volume108
dc.identifier.issue8
dc.identifier.startpage2570
dc.identifier.endpage2579
dc.identifier.doihttps://doi.org/10.1016/j.xphs.2019.03.006
dc.identifier.urnURN:NBN:no-79163
dc.type.documentTidsskriftartikkelen_US
dc.type.peerreviewedPeer reviewed
dc.source.issn0022-3549
dc.identifier.fulltextFulltext https://www.duo.uio.no/bitstream/handle/10852/76064/2/Wu%2Bet%2Bal._2019-CRISTin.pdf
dc.type.versionAcceptedVersion


Files in this item

Appears in the following Collection

Hide metadata